An open-label, 52-week extension to a 24-week, Multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group evaluation of the efficacy, safety, and tolerability of the once-daily rivastigmine patch formulation in patients with probable Alzheimer's disease (MMSE 10-20)
Latest Information Update: 09 Aug 2016
At a glance
- Drugs Rivastigmine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Novartis
- 14 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 May 2009 Planned number of patients changed from 500 to 637 as reported by ClinicalTrials.gov.